All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Novo Nordisk A/S has identified novel fatty acid modified urocortin 2 derivatives acting as CRF2 receptor agonists reported to be useful for the treatment of obesity and type 2 diabetes.
